C4 Therapeutics c4therapeutics.com

C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. The company's Degronimid platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previo...Show all

C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. The company's Degronimid platform incorporates highly selective small molecule binders to target disease-caus...Show all

Company (Alive / Active)

All investors data 7 Investors

• Cobro Ventures
• Cormorant Asset Management
• EG Capital Group
• Novartis Venture Funds
• Roche Venture Fund

There is no Investors data available for this company. Please select another tab.

There is no Board of Directors data available for this company. Please select another tab.

Board Members

There is no Competitors data available for this company. Please select another tab.

Competitors

See all 0 competitors

Patents